VectorY Therapeutics has secured exclusive evaluation rights to Shape Therapeutics’ engineered AAV5-derived capsid, SHP-DB1, optimized for deep brain penetration in preclinical models. The agreement could yield Shape up to $1.2 billion in upfront and milestone payments, reflecting the high value of next-generation delivery technologies for neurodegenerative diseases. Their collaboration aims to enhance intravenous delivery of genetic medicines targeting Huntington's, ALS, and Alzheimer's disease, leveraging SHP-DB1’s superior neuronal access in non-human primates.